Firstly, the cross-sectional design precluded longitudinal assessment of disease progression in patients with ALS, thereby restricting our ability to comprehensively evaluate the lasting impact of adiponectin on the patient population. Here, ADIPOQ is linked to amyotrophic lateral sclerosis.